Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368382 | 0.95 | TYMP (0.32) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL16368400 | 0.94 | TYMP (0.34) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL16368383 | 0.92 | TYMP (0.34) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL16368399 | 0.91 | TYMP (0.34) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL16368381 | 0.91 | TYMP (0.34) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL16368385 | 0.88 | TYMP (0.34) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL18198302 | 0.85 | TYMP (0.39) | TYMPADORA3ADORA2AADORA1 | |
| SCHEMBL16214161 | 0.81 | TYMP (0.32) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL16368306 | 0.81 | P2RY6 (0.32) | TYMP | |
| SCHEMBL16375322 | 0.81 | NT5E (0.30) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194793-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TYMP 10/4885ADORA3 79/4885ADORA2A 71/4885 |
| US-20180194793-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | TYMP 13/4885ADORA3 63/4885ADORA2A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.